Waystar Holding Corp.

Waystar Holding Corp. (WAY) Market Cap

Waystar Holding Corp. has a market capitalization of $3.64B.

Price: $19.00

▲ 0.59 (3.20%)

Market Cap: 3.64B

NASDAQ ¡ time unavailable

CEO: Matthew J. Hawkins

Sector: Technology

Industry: Information Technology Services

IPO Date: 2024-06-07

Website: https://waystar.com

Waystar Holding Corp. (WAY) - Company Information

Market Cap: 3.64B|Sector: Technology

Company Profile

Waystar Holding Corp. is dedicated to developing a cloud-based software platform designed to streamline financial transactions within the healthcare industry. Their comprehensive system offers a suite of functionalities, including pre-approving finances, supporting patients with billing, overseeing claims and payments, actively preventing and recovering denied claims, enhancing revenue capture, and providing insightful analytics and reporting. The company's main clientele operates within the healthcare sector. Established in 2017, Waystar Holding Corp. is headquartered in Lehi, Utah.

Analyst Sentiment

92%
Strong Buy

From 17 Active Polls

1Y Forecast: $35.62

▲ +87.5% Potential Upside

Consensus Target Metrics

Low Bound

$27

Median

$36

High Bound

$43

Average

$36

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$35.62
▲ +87.47% Upside
Low Target
$27.00
42% Risk
Median Target
$36.00
89% Mid
High Target
$43.00
126% Max
Consensus
Buy
17 / 17 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)3,6444,6216,2686,6117,0856,4336,3324,7853,585
Enterprise Value ($M)5,0966,0737,6947,4338,0507,4687,4135,9244,893
Price to Earnings Ratio (P/E)27.1426.2181.8852.6753.7854.9483.41221.35-31.63
Price/Earnings-to-Growth Ratio (PEG)—7.706.30—9.7010.8750.1993.22-7.29
Price to Sales Ratio (P/S)3.1514.7220.6524.6126.1825.0925.9419.9315.28
Price to Book Ratio (P/B)0.921.171.622.052.232.062.061.571.22
Price to Free Cash Flow Ratio (P/FCF)12.4066.41109.5486.8277.86109.36108.1568.16417.72
Enterprise Value to Sales (EV/Sales)—19.3525.3527.6729.7429.1230.3724.6720.86
Enterprise Value to EBITDA (EV/EBITDA)12.3250.2075.5280.2481.9275.7581.3067.8393.17
Debt to Equity Ratio3.510.380.390.390.400.400.410.410.47

⚡ WAY Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$19.00
Intrinsic Value$73.60
Market Alignment
Undervalued by 287.4%relative to calculated intrinsic value
9.00%
Exp: 14%14%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$1.35B
Perpetuity TV Value$25.48B
Discounted TV (PV)$10.76B
TV Weighting %65.0%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 WAYSTAR HOLDING CORP (WAY) — Investment Overview

🧩 Business Model Overview

Waystar provides infrastructure software and services that connect healthcare providers to the complex ecosystem required to get claims paid. The platform supports workflow across revenue cycle and payments, including eligibility and claims processing, payment remittance, and related administrative functions that sit between provider systems (EHR/PM) and payers (commercial and government). The economic “how it works” is two-sided in practice: (1) providers rely on Waystar’s connectivity and processing capabilities to reduce operational friction in claims and payments, and (2) payer reimbursement outcomes depend on accurate, standards-compliant data exchange. As a result, Waystar’s value proposition is heavily tied to integration reliability, rules/format adherence, and operational throughput—elements that become embedded inside provider organizations’ processes and vendor stacks.

💰 Revenue Streams & Monetisation Model

Waystar monetizes primarily through a mix of recurring platform/technology fees and transaction-linked processing revenue. Key characteristics typically include:
  • Recurring subscription and usage-based fees tied to the provider’s deployment footprint, module selection, and continued processing activity.
  • Transaction-based revenue associated with high-volume administrative events such as claims and payment processing flows.
  • Service and implementation revenue that supports onboarding, integration, and operational enablement.
Margin drivers center on (1) operating leverage from software-centric processing at scale, (2) retention of integrated workflows that sustain recurring revenue, and (3) the ability to improve automation and straight-through processing rates, which reduces labor intensity per processed administrative event over time.

🧠 Competitive Advantages & Market Positioning

Waystar’s moat is rooted in switching costs and data gravity, reinforced by deep operational know-how in healthcare payment rails.
  • High switching costs (embedded integrations): Once connected to a provider’s core systems and established workflows, replacing the connectivity layer and processing logic requires extensive re-integration, remapping of data formats, retraining, and operational validation—work that carries both cost and reimbursement risk.
  • Data gravity (process familiarity): The platform accumulates operational context—connectivity patterns, rules handling, and mapping behaviors—making continued performance more efficient as the workflow matures.
  • Network effects (payer/provider connectivity): While healthcare administrative networks are not “social networks,” there is a practical network dynamic: the more reliably a platform supports a broad set of payer arrangements and transaction types, the more attractive it becomes as a consolidated connectivity and processing layer for providers.
Competitive benchmarking (primary rivals):
  • R1 RCM: Greater emphasis on revenue cycle management services and software for provider billing/reimbursement workflows. Waystar’s differentiation centers more on the connectivity and processing infrastructure layer that supports claims and payments.
  • Change Healthcare (UnitedHealth): Strong position across healthcare payment/administrative technologies and RCM-adjacent infrastructure. Waystar competes on platform integration depth and reliability as a critical interchange between provider systems and payer processes.
  • Inovalon: Focus on data and analytics in provider-facing healthcare administration. Waystar’s advantage is less about clinical analytics and more about operational connectivity and payment processing enablement.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, Waystar’s growth is supported by structural demand for administrative simplification and automation in healthcare reimbursement:
  • Continued shift toward technology-enabled revenue cycle operations: Providers seek productivity improvements and process standardization to manage staffing constraints and administrative burden.
  • Complexity expansion in payment requirements: Ongoing payer rule variability, coding/edit requirements, and government program administration sustain demand for connectivity layers that can handle change with minimal operational disruption.
  • Broadening the platform footprint within provider organizations: Once connectivity and processing are in place, expansion across additional administrative workflows and modules is structurally easier than switching vendors.
  • Automation and straight-through processing: Investment in processing logic, rules handling, and workflow tooling supports improved throughput and reduced manual intervention—supporting both customer value and commercial durability.
  • Consolidation and vendor rationalization: Market participants often consolidate administrative vendors to reduce integration complexity, positioning Waystar as an infrastructure layer that can capture incremental wallet share.

⚠ Risk Factors to Monitor

Key structural risks that can impact unit economics or competitive position include:
  • Regulatory and compliance exposure: Healthcare administrative systems are subject to evolving regulations (privacy/security, billing rules, and payer/program administration). Compliance failures can be costly and disruptive.
  • Cybersecurity and operational resilience: Payment and claims infrastructure is mission critical; outages, data integrity issues, or ransomware events can lead to customer losses and remediation costs.
  • Payer/provider contract dynamics: Changes in pricing power, reimbursement volumes, or contract terms can pressure transaction-linked economics.
  • Concentration and implementation risk: Revenue can be sensitive to the timing and success of onboarding large customers, along with retention if performance or integration milestones slip.
  • Competitive displacement in adjacent layers: Larger RCM incumbents and payer-linked platforms can offer bundled solutions that create pressure on standalone economics. Sustaining differentiation requires continued performance and integration reliability.

📊 Valuation & Market View

Markets typically value healthcare administrative software and processing platforms using a blend of metrics emphasizing durability and scale, such as:
  • Revenue quality: recurring and usage-linked revenue profiles often receive a premium to purely transactional models.
  • Operating leverage: the trajectory of margins as fixed infrastructure is leveraged over processing volume.
  • Cash conversion: the ability to convert earnings into free cash flow given working-capital dynamics typical of payment-related workflows.
The primary “needle movers” for investor perception in this segment tend to be customer retention and expansion within integrated accounts, evidence of sustained transaction throughput without quality/regulatory setbacks, and stability in contract economics across payer and provider networks.

🔍 Investment Takeaway

Waystar’s long-term investment case rests on infrastructure-level stickiness in healthcare payments and revenue cycle administration. Its moat is primarily switching costs created by deep integrations and embedded workflows, reinforced by data gravity and practical connectivity/network advantages across payer/provider processes. Provided regulatory compliance, cybersecurity resilience, and processing reliability remain intact, Waystar is positioned to sustain recurring revenue durability while expanding platform usage across a large and structurally complex end market.

⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for WAY.

seekingalpha.com•2026-06-18

Waystar: Silently Taking Over Healthcare Billing

Waystar Holding Corp. is rated buy, with an 85% upside to a $37 price target, as current share price reflects temporary private equity (PE) selling pressure, not business fundamentals. Waystar's revenue grew 22% YoY, profit margins remain above 40%, and a $200M buyback offsets PE overhang; 23 of 24 analysts rate it Buy/Strong Buy. The Iodine acquisition and AI-powered AltitudeAI suite expand WAY's end-to-end billing solutions, driving new client wins and high retention in a $100B+ addressable market.

prnewswire.com•2026-06-09

New Research Reveals Healthcare Leaders Who Unite Financial and Clinical Data Recover Millions in Previously Missed Revenue

Healthcare leaders show unanimous interest in a single AI-powered platform connecting the mid-cycle to the final claim — yet 86% are still leaving revenue on the table LEHI, Utah and LOUISVILLE, Ky., June 9, 2026 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today released The State of the Mid-Revenue Cycle report.

seekingalpha.com•2026-06-08

Baron Discovery Fund Q1 2026: Who Moved The Needle

In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.

zacks.com•2026-05-29

TBRG vs. Waystar: Which Healthcare RCM Stock Is the Better Bet Now?

WAY's AI-driven RCM growth and strong Q1 results stand out, while TruBridge trades near its pending buyout price with limited upside.

prnewswire.com•2026-05-20

Waystar to Speak at William Blair Conference

LEHI, Utah and LOUISVILLE, Ky., May 20, 2026 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will speak at the 46th Annual William Blair Growth Stock Conference on Tuesday, June 2, 2026, at 10:40 a.m.

247wallst.com•2026-05-19

AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers

Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution.

prnewswire.com•2026-05-19

Waystar Announces $200 Million Share Repurchase Authorization, Reflecting Confidence in Long-Term Outlook

LEHI, Utah and LOUISVILLE, Ky., May 19, 2026 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that its Board of Directors authorized a stock repurchase plan for up to $200 million of the Company's common stock.

seekingalpha.com•2026-05-12

Waystar: Revised Guidance Does Not Imply Demand Weakness

Waystar remains a buy as Q1 results confirm robust demand, with provider solutions leading and AI integration strengthening the platform story. WAY's Q1 revenue grew 22% y/y to $313.9M, with subscription revenue up 38% and net revenue retention at 111%, highlighting strong customer engagement. Patient payment solution headwinds stem from a faster shift to digital, seen as a near-term timing issue rather than a structural demand problem.

prnewswire.com•2026-05-05

Waystar Named to TIME100 Most Influential Companies

Wins TIME Impact in AI Award for purpose-built innovation in healthcare LEHI, Utah and LOUISVILLE, Ky., May 5, 2026 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced it has been named to the TIME100 Most Influential Companies list and recognized as the TIME Impact in AI award winner for delivering proven outcomes across the healthcare revenue cycle.

seekingalpha.com•2026-04-30

Waystar Holding Corp. (WAY) Q1 2026 Earnings Call Transcript

Waystar Holding Corp. (WAY) Q1 2026 Earnings Call Transcript

zacks.com•2026-04-29

Waystar (WAY) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Waystar (WAY) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com•2026-04-29

Waystar Holding (WAY) Q1 Earnings and Revenues Surpass Estimates

Waystar Holding (WAY) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.32 per share a year ago.

prnewswire.com•2026-04-29

Waystar Reports First Quarter 2026 Results

Q1 revenue of $313.9M, up 22% YoY Q1 net income of $43.3M and non-GAAP net income of $81.2M Q1 net income margin of 14%; adjusted EBITDA margin of 43% LEHI, Utah and LOUISVILLE, Ky., April 29, 2026 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the first quarter ended March 31, 2026.

zacks.com•2026-04-28

WAY vs. FFIV: Which Stock Should Value Investors Buy Now?

Investors with an interest in Internet - Software stocks have likely encountered both Waystar Holding (WAY) and F5 Networks (FFIV). But which of these two stocks presents investors with the better value opportunity right now?

fool.com•2026-04-24

Capricorn Fund Managers Dumps $18.4 Million Worth of Waystar Stock in Q1

Waystar delivers cloud-based payment solutions for healthcare providers, supporting over $1 billion in annual revenue with a SaaS model.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"WAY reported Q1 2026 Revenue of $313.9M (+9.9% QoQ, +22.4% YoY) and Net Income of $43.3M (+116.6% QoQ, +48.0% YoY). EPS was $0.22 diluted ($0.23 basic). Profitability improved markedly: gross margin rose to 69.1% from 56.2% in Q4 2025 and was above Q1 2025 (67.5%). Net margin expanded to 13.8% (vs. 6.6% in Q4 2025 and 11.4% in Q1 2025), while operating income margin increased to 25.6% from 25.0% in Q4 2025. Cash flow also strengthened. Operating cash flow was $84.9M and free cash flow was $69.6M, both higher than the prior quarter. Balance sheet resilience appears strong on an overall basis: total assets were $5.84B with equity of $3.94B, and the company is effectively net-cash (net debt -$3.7M). Debt is low versus equity. Total shareholder returns are currently pressured: the stock price is $25.8 and is down -29.7% over 1 year (a negative momentum signal). With no dividends reported and no buybacks in the quarter, shareholder return is dominated by price performance. Analyst consensus target ($36.15) implies potential upside of ~40% from the current price."

Revenue Growth

Good

Revenue grew +9.9% QoQ (from $303.5M) and +22.4% YoY (from $256.4M), indicating improving top-line momentum.

Profitability

Positive

Margins expanded meaningfully: net margin improved to 13.8% (from 6.6% QoQ) and 11.4% YoY; gross margin rose to 69.1% from 56.2% in the prior quarter.

Cash Flow Quality

Positive

Operating cash flow was $84.9M with free cash flow of $69.6M; both improved vs. Q4. No dividends and no buybacks were reported this quarter, so shareholder cash return is limited.

Leverage & Balance Sheet

Good

Equity is stable at ~$3.94B and leverage is low with net debt of -$3.7M (net cash position). Total assets remain sizable at ~$5.84B.

Shareholder Returns

Neutral

Stock has negative 1-year momentum (-29.7% 1y_change). With no dividends and no buybacks indicated, total shareholder returns have been weak.

Analyst Sentiment & Valuation

Neutral

Consensus target of $36.15 vs. current $25.8 suggests ~+40% upside. Valuation multiples in the ratios appear elevated, but the target implies analysts see meaningful earnings power.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Waystar started 2026 with strong top-line and margin execution: $314M revenue (+22% YoY) and $135M adjusted EBITDA (+26% YoY) drove a 43% margin, helped by mix shift toward higher-margin provider solutions (organic +double rate vs lower-margin patient payments). The key offset came from patient-payment volume headwinds—primarily accelerated print-to-digital conversion—plus health care coverage changes and weather, which management framed as non-competitive and baked into updated 2026 seasonality (Q2 flat to +1% sequential; Q3 +1%–3%). AI is positioned as both a platform defensibility mechanism and a TAM expansion lever, with ~40% of new bookings linked to AI and embedded workflows generating ~40% of revenue. Early SKU proof points included $3M net revenue per 10,000 discharges (prebill anomaly detection) and a 50% expected collections lift (Altitude AI). Iodine integration is progressing ahead of plan, with early cross-sell traction exceeding expectations.

AI IconGrowth Catalysts

  • AI-powered capabilities drove ~40% of new bookings in Q1, with clients leaning toward prevention/automation/visibility vs downstream rework
  • Prebill anomaly detection solution: estimated $3 million net revenue per 10,000 patient discharges and 5x recovered revenue over 3 years (early deployments)
  • Altitude AI patient financial experience: expected 50% increase in collections
  • Recruitment solution (built on Altitude AI): providers reduced reconciliation time by 80%+ and an early adopter health system matched $32 million in revenue risk (~13 FTE equivalent)

Business Development

  • Added 42 new clients in Q1 with >$100,000 trailing 12-month revenue (win rates exceeded historical averages)
  • Early adopter health system (unnamed) for recruitment SKU demonstrating $32 million matched revenue risk
  • Iodine integration generating early cross-sell traction (no named counterparties provided in transcript)

AI IconFinancial Highlights

  • Revenue $314M (+22% YoY); organic revenue +11% YoY
  • Adjusted EBITDA $135M (+26% YoY); adjusted EBITDA margin 43% (shifted toward higher-margin provider solutions)
  • Net revenue retention ~111% (slightly above 108%–110% historical range)
  • Subscription revenue $172M (+38% YoY; +3% sequential), 55% of total revenue
  • Volume-based revenue $139M (+7% YoY; +4% sequential) impacted by patient payment headwinds
  • Patient payments pressured by (1) accelerated print-to-digital patient statements conversion, (2) health care coverage changes, and (3) weather-related dynamics (non-competitive, non-product-driven)
  • Capital position: $159M cash/equivalents/short-term investments; $1.5B gross debt; unlevered FCF $90M; 67% conversion of adjusted EBITDA to unlevered FCF; net leverage 2.7x vs 3.0x at FY end
  • Ratings: Moody’s and S&P upgraded Waystar’s debt facility in past couple months

AI IconCapital Funding

  • No buyback amount disclosed in transcript
  • Debt: $1.5B gross debt; net leverage 2.7x as of March 31, 2026
  • Runway indicators: $159M cash/equivalents/short-term investments; 67% adjusted EBITDA to unlevered FCF conversion

AI IconStrategy & Ops

  • Shift from task-level automation to Agentic workflows; nearly 40% of revenue generated by AI embedded workflows
  • Integration progress on Iodine: ahead of plan; fully integrated AI talent; early cross-sell traction exceeding expectations
  • Expanded prebill anomaly detection and Agentic intelligence capabilities introduced at spring innovation showcase
  • Digital transformation underway: accelerated conversion from print to digital statements; management stated top-line impact is neutralized at margin dollars/cash flow level

AI IconMarket Outlook

  • Reaffirmed revenue guidance: $1.274B–$1.294B (midpoint $1.284B), +17% YoY; assumes normalized organic revenue growth ~10%
  • Reaffirmed adjusted EBITDA guidance: $530M–$540M (midpoint $535M)
  • Updated seasonality expectation: previously guided 1%–3% sequential quarterly growth throughout 2026 with Q3 low end; now expects Q2 flat to +1% sequential and Q3 +1%–3%
  • Management expects reduced variability in patient-payment seasonality in 2026 vs past couple years

AI IconRisks & Headwinds

  • Patient payment volume pressure in Q1: accelerated print-to-digital conversion, health care coverage changes, and weather-related impacts
  • Recruitments/cash flow volatility risk: payers take back >$40B/year via recoupments/offsets; recruitment growth >2x overall claim volume (heightened timing variability until automation improves transparency)
  • Deal conversion timing: larger platform deals still take ~6 to 18 months for full revenue realization

Q&A: Analyst Interest

  • AI TAM and future revenue impact: Management tied AI to a larger autonomous revenue cycle platform TAM, citing a McKinsey service-to-software shift. They argued AI monetizes via new SKUs and replaces manual work, positioning AI as a lifetime tailwind rather than a short-term tweak.
  • Patient payments volatility drivers and isolation vs guidance: Management attributed patient payment pressure mainly to faster print-to-digital conversion, not AI competition. Steve cited provider solutions sustaining growth (75% revenue, ~13%–14% organic Y/Y over six quarters). They said conversion is top-line headwind but neutral on margin dollars/cash flow.
  • Bookings composition and timing of realization: Management described momentum across new and cross-sell/upsell, with million-dollar bookings >2x quarterly average of past three years continuing. They noted larger deals still take 6–18 months to show up in revenue, while starting Q2 with the largest qualified pipeline and an elevated implementation backlog.

Sentiment: MIXED

Note: This summary was synthesized by AI from the WAY Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for WAY.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (WAY)

© 2026 Stock Market Info — Waystar Holding Corp. (WAY) Financial Profile